Is This Growth Stock Undervalued?
Biotech company Bluebird Bio (NASDAQ: BLUE) is currently riding high. Despite these accomplishments, Bluebird is still a tiny company with a market cap of just $475 million. Of note, Skysona had previously earned marketing authorization in Europe, but Bluebird exited the European market last year for reasons that may also prove to be a challenge in the U.S. (more on that in a bit).